How Researchers Are Building on Today’s CLL Treatments
- Treatment for chronic lymphocytic leukemia (CLL) continues to evolve, with newer targeted therapies — especially BTK and BCL‑2 inhibitors — helping many people avoid chemotherapy and maintain long‑term disease control.
- Pirtobrutinib, a newer non‑covalent BTK inhibitor, is now FDA‑approved for relapsed or refractory CLL/SLL after prior treatment with a covalent BTK inhibitor and is being studied to see whether using it earlier could lead to deeper or longer‑lasting responses.
- Researchers are also exploring next‑generation options such as BTK degraders and newer BCL‑2 inhibitors, aiming to expand treatment choices and determine the optimal sequence of therapies to deliver the strongest, most tolerable, and longest‑lasting results for each patient.
Pirtobrutinib (brand name Jaypirca) is a newer, non-covalent BTK inhibitor that is already an important treatment option for people whose CLL has progressed after treatment with a covalent BTK inhibitor.
Read MoreEvolving Treatment Options
Another area of research involves BCL-2 inhibitors like Venetoclax, which has become an important part of CLL treatment. Researchers are studying newer drugs in this class to determine whether they might provide advantages in certain situations.
Research is also moving beyond drugs that simply block BTK. BTK degraders are an emerging class of medicines designed to remove the BTK protein itself rather than simply blocking its activity. Early clinical studies are showing promising results, although these treatments remain investigational.
Expert Resources for CLL Patients
- Changing the Way CLL is Treated: What are BTK Inhibitors?
- Chronic Lymphocytic Leukemia (CLL): How Can Pirtobrutinib Fit Into My Treatment Plan?
- BTK Inhibitors: Finding The Right Fit For Chronic Lymphocytic Leukemia (CLL) Patients
- BTK Inhibitors for CLL Treatment: What Side Effects Can I Expect and How Do I Manage Them?
- An Oral Medicine for People With Relapsed CLL: Idelalisib
Dr. Kline describes the potential of these newer approaches: “We’ve got new drugs in the pipeline all the time. So venetoclax is a very good BCL2 inhibitor. There’s another BCL-2 inhibitor in development that seems like it may just work better, maybe a stronger, more effective drug. So those trials, again, are underway. We’ll know more about whether it should replace venetoclax in certain circumstances soon. And then new families of drugs, again, some of them looking for new ways to target similar targets. So BTK degraders, which don’t just bind to the receptor and block the pathway, but actually permanently degrade the receptor, are under development.”
The rapid development of new treatments is encouraging. Researchers are investigating new BTK inhibitors, BTK degraders, BCL-2 inhibitors, cellular therapies, and other approaches which may eventually provide options for people whose CLL has become resistant to existing therapies.
The Future of CLL Treatment
Dr. Kline emphasizes that the ultimate goal is to give doctors and patients more choices: “We know that blocking this Bruton tyrosine kinase pathway is really important for treating CLL. So figuring out whether that degrader might be an even more effective way of doing it or, again, might be effective in some patients for whom BTK inhibitors have stopped working. Those drugs are in development. It’ll be great to have more tools in our toolbox if they work.”
The future of CLL treatment may ultimately involve choosing from a growing number of targeted therapies and using them in the sequence that provides each individual patient with the best balance of disease control, durability, and quality of life.
Learn more about SurvivorNet's rigorous medical review process.
